Enablex · DIN 02273225 · 15 mg · extended release tablet
Limited Use, Reason for Use code 290 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 290 required
Write on scriptReason for Use code 290 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 290
Reason for Use code 290
For patients with urinary frequency, urgency or urge incontinence who have:
Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects.
NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed.
Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Enablex · DIN 02273225
Manufacturer: Searchlight Pharma Inc.; listing date 2011-12-15
Health Canada: Marketed since 2019-04-02 · brand ENABLEX · ATC G04BD10 DARIFENACIN · form Tablet (extended-release) · route Oral · ingredients DARIFENACIN (DARIFENACIN HYDROBROMIDE) 15 MG · company Searchlight pharma inc · schedule Prescription
Ministry pays: $0.8058 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02273225)
Source record
DIN 02273225: Enablex
Raw flags: sec12=Y, sec3=Y
Item: 920000641; group id 908; item number 2176; lccId 00216; manufacturer id SLP
Source form: ER Tab; strength: 15mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.6116; ministry $0.8058
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02273225
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75872
Interchangeable products
Apo-Darifenacin · DIN 02452529 · $0.8058
Jamp Darifenacin · DIN 02491877 · $0.8058
Shortage status: resolved shortage (ended August 26, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02273225
Shortage record checked October 6, 2026